Mrna

© GettyImages/niphon

Moderna to develop mRNA therapeutic for very rare disease

By Jane Byrne

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Pic:getty/richarddrury

mRNA and beyond: Opportunities for US biologics

By Staff reporter

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

© GettyImages/Fokusiert

Moderna starts process to obtain BLA for Covid-19 shot

By Jane Byrne

Moderna has initiated the rolling submission process with the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) to distribute and market its mRNA COVID-19 vaccine in the US for use in individuals aged 18 and older.